14 hasil untuk "Annette M. Lim"
Menampilkan 1–14 · 1,12 detik · RSS
-
Artikel Jurnal
Immunotherapy response and resistance in cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma (CSCC) is one of the most common types of cancer globally. Over the last decade, the treatment of the disease has been transformed with the use of immune checkpoint blockade. In the recurrent and metastatic setting, ~50% overall response rates can be achieved, with…
-
Artikel Jurnal Teks lengkap
Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
Despite cutaneous squamous cell carcinoma (CSCC) being the second most common skin cancer worldwide, there were no approved systemic therapies for patients with unresectable and/or metastatic disease prior to the advent of anti-programmed cell death protein-1 (anti-PD1) agents cemiplimab and…
-
Artikel Jurnal
Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma
Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1…
-
Artikel Jurnal
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
BackgroundCutaneous squamous cell carcinoma (CSCC) of the head and neck can require complex and disfiguring surgery in order to achieve cure, which can be morbid and negatively impact patient quality of life. The management of advanced CSCC has been revolutionized by immunotherapy with current…
-
Artikel Jurnal
Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy
Abstract Background Cutaneous squamous cell carcinoma (CSCC) has a propensity for perineural spread (PNS) which is associated with poorer treatment outcomes. Immunotherapy is the new standard of care treatment for advanced CSCC resulting in durable responses. PNS is not captured by traditional…
-
Artikel Jurnal
A two-phase study investigating the quality of life benefit of additional 0.5% cocaine mouthwash to institutional standard of care mucositis management in head and neck cancer patients undergoing radiotherapy or chemoradiotherapy
Abstract Background Mucositis remains a challenging complication of radiotherapy or chemoradiotherapy (CRT) for head and neck cancer (HNC) patients. There is limited data on the safety or effectiveness of cocaine mouthwash to treat mucositis. Methods This was single centre, prospective sequential…
-
Artikel Jurnal
FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
Abstract Background The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months…
-
Artikel Jurnal
Low-coverage whole-genome sequencing of extracellular vesicle-associated DNA in patients with metastatic cancer
Abstract Low-coverage whole-genome sequencing (LC-WGS) can provide insight into oncogenic molecular changes. Serum extracellular vesicles (EV) represent a novel liquid biopsy source of tumoral DNA. This study compared copy number alteration (CNA) profiles generated from LC-WGS of formalin-fixed…
-
Artikel Jurnal
Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease
Abstract We investigated whether a unique immune response was instigated with the development of oral tongue squamous cell carcinomas (OTSCC), with/without nodal involvement, with/without recurrent metastatic disease, or within tumor involved nodes. One hundred and ten formalin‐fixed…
-
Artikel Jurnal
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Background To provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).Methods Patients received cemiplimab 3 mg/kg every 2…
-
Artikel Jurnal
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Background Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and the pivotal Phase 2 study (NCT02760498). Here we…
-
Artikel Jurnal
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
Background Cemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candidates for curative surgery or curative radiation, using an…
-
Artikel Jurnal
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) are an important class of cancer treatment. Endocrine immune-related adverse events (E-irAEs) account for a significant proportion of irAEs in ICI-treated patients. Diagnosing E-irAEs accurately and timely can be challenging in the absence of clear categorization…